{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:40:34Z","timestamp":1760204434468,"version":"3.37.3"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T00:00:00Z","timestamp":1226448000000},"content-version":"vor","delay-in-days":8382,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Develop Med Child Neuro"],"published-print":{"date-parts":[[1985,12]]},"abstract":"<jats:sec><jats:title>SUMMARY<\/jats:title><jats:p>Clonidine, an alpha<jats:sub>2<\/jats:sub>\u2010adrenoreceptor agonist, is useful for treating some patients with Tourette syndrome, and it has been suggested that their noradrenergic receptors are \u2018subsensitive\u2019. The authors measured plasma norepinephrine and specific binding of<jats:sup>3<\/jats:sup>H\u2010clonidine and<jats:sup>3<\/jats:sup>H\u2010yohimbine, an alpha<jats:sub>2<\/jats:sub>\u2010adrenoreceptor antagonist, to receptors on platelet membranes from children with Tourette syndrome. Before clonidine treatment, plasma norepinephrine, the maximum number of binding sites and the dissociation constants for both ligands were the same as for the controls. After two weeks of treatment there was little clinical improvement, but the number of binding sites for<jats:sup>3<\/jats:sup>H\u2010yohimbine decreased and plasma norepinephrine also decreased in four of the five patients. Over the next six months all five patients continued to improve clinically, but both indices of noradrenergic activity returned towards baseline values. The data suggest that clonidine's action may be independent of its prominent effects on alpha<jats:sub>2<\/jats:sub>\u2010adrenergic receptors and norepinephrine release.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESUME<\/jats:title><jats:p><jats:italic>Effet de la clonidine sur tes alpha<jats:sub>2<\/jats:sub>\u2010adr\u00e9nor\u00e9cepteurs plaquettaires et sur la noradrenaline plasmatique chez les enfants pr\u00e9sentant un syndrome de Tourette<\/jats:italic><\/jats:p><jats:p>La clonidine, agoniste des alpha<jats:sub>2<\/jats:sub>\u2010adr\u00e9nor\u00e9cepteurs, est utile dans le traitement de quelques sujets atteints d'un syndrome de Tourette et il a \u00e9t\u00e9 sugg\u00e9r\u00e9 que leur r\u00e9cepteurs noradr\u00e9nergiques sont \u201csous\u2010sensibles\u201d. Les auteurs ont mesure la noradr\u00e9naline plasmatique et la l\u00e9sion sp\u00e9cifique de la<jats:sup>3<\/jats:sup>H\u2010clonidine et de la<jats:sup>3<\/jats:sup>H\u2010yohimbine, antagoniste des alpha<jats:sub>2<\/jats:sub>\u2010adr\u00e9nor\u00e9cepteurs, aux r\u00e9cepteurs des membranes plaquettaires chez des enfants atteints d'un syndrome de Tourette. Avant le traitement par clonidine, la noradrenaline plasmatique, le nombre maximum de sites de liaison et les constantes de dissociation pour les deux ligands \u00e9taient identiques \u00e0 ceux des contr\u00f4les. Apr\u00e8s deux semaines de traitement, il y avait peu d'am\u00e9lioration clinique, mais le nombre des sites de liaison pour la<jats:sup>3<\/jats:sup>H\u2010yohimbine avait d\u00e9cru et les taux de noradr\u00e9naline plasmatique avaient \u00e9galement d\u00e9crus chez quatre des cinq malades. Pass\u00e9s les six mois suivants, les cinq patients avaient continu\u00e9\u00e0 s'am\u00e9liorer cliniquement mais tous les indices de l'activit\u00e9 noradr\u00e9nergique \u00e9taient revenus \u00e0 des valeurs normales. Ces donn\u00e9es sugg\u00e8rent que l'action de la clonidine pourrait \u00eatre ind\u00e9pendante de ses effets pr\u00e9dominants sur les r\u00e9cepteurs alpha<jats:sub>2<\/jats:sub>\u2010adr\u00e9nergiques et la lib\u00e9ration de noradr\u00e9naline.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1469-8749.1985.tb03804.x","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T05:47:19Z","timestamp":1279172839000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["EFFECT OF CLONIDINE ON PLATELET ALPHA<sub>2<\/sub>\u2010ADRENORECEPTORS AND PLASMA NOREPINEPHRINE OF CHILDREN WITH TOURETTE SYNDROME"],"prefix":"10.1111","volume":"27","author":[{"given":"Faye","family":"Silverstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael V.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(76)90136-9"},{"volume-title":"The Pharmacological Basis of Therapeutics","year":"1980","author":"Blaschke T. F.","key":"e_1_2_1_3_1"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00605989"},{"volume-title":"Gilles de la Tourette Syndrome","year":"1982","author":"Bruun R. D.","key":"e_1_2_1_5_1"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410060109"},{"key":"e_1_2_1_7_1","unstructured":"Cameron O. Hollingsworth P. J. Nesse R. Curtis G. Smith C. B.(1983) \u2018Platelet alpha2\u2010adrenoreceptors in panic anxiety.Abstracts of the American Psychiatric Association Abstract 55."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)90679-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)61046-3"},{"key":"e_1_2_1_10_1","first-page":"551","article-title":"Clonidine in Tourette's syndrome","volume":"2","author":"Young J. G.","year":"1979","journal-title":"Lancet"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780250036004"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1981.01780370029003"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(81)90052-2"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.5.586"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1974.tb02715.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(76)90375-1"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6849119"},{"key":"e_1_2_1_18_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0031-6997(25)06843-7","article-title":"Presynaptic regulation of the release of catecholamines","volume":"32","author":"Langer S. Z.","year":"1981","journal-title":"Pharmacological Reviews"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)61504-1"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.247.8.1168"},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0006-291X(80)80044-1","article-title":"Characterization of alpha2\u2010adrenergic receptors in human platelets using [3H]\u2010yohimbine","volume":"97","author":"Motulsky H. J.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(77)90070-4"},{"key":"e_1_2_1_23_1","first-page":"839","article-title":"Clonidine treatment decreases platelet alpha2\u2010adrenoreceptors in hypertensive patients","volume":"43","author":"Schneider R. H.","year":"1984","journal-title":"Federation Proceedings"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100081011"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0026-895X(25)12529-7","article-title":"Characterizationof alpha2\u2010adrenergic receptors in human platelets using [3H]\u2010clonidine","volume":"19","author":"Shattil S. J.","year":"1981","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"e_1_2_1_26_1","article-title":"Clonidine in Tourette's syndrome: clinical and alpha2\u2010adrenoreceptor responses","volume":"34","author":"Silverstein F. S.","year":"1984","journal-title":"Neurology"},{"key":"e_1_2_1_27_1","first-page":"1311","article-title":"Cholinergic treatment in the Tourette syndrome","volume":"302","author":"Stahl S. M.","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(75)90276-0"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.11.1315"}],"container-title":["Developmental Medicine &amp; Child Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1469-8749.1985.tb03804.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1469-8749.1985.tb03804.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T22:39:31Z","timestamp":1740263971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1469-8749.1985.tb03804.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1985,12]]}},"alternative-id":["10.1111\/j.1469-8749.1985.tb03804.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-8749.1985.tb03804.x","archive":["Portico"],"relation":{},"ISSN":["0012-1622","1469-8749"],"issn-type":[{"type":"print","value":"0012-1622"},{"type":"electronic","value":"1469-8749"}],"subject":[],"published":{"date-parts":[[1985,12]]},"assertion":[{"value":"2008-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}